How would you define cross-functional collaboration in the context of life sciences product launches?

For me, cross-functional collaboration isn’t just about sitting at the same table but moving with shared urgency and purpose. In life sciences, launching a product requires the seamless alignment of procurement, quality, technical, and supply functions—what we call PQTS+. Each group has a critical role, and the key is to break silos early. You need clear timelines, transparent data, and mutual accountability. The goal is simple: ensure a product moves from R&D to market without delays, deviations, or regulatory hiccups. Patients benefit faster when that happens— that’s what drives me.

What’s been your approach to aligning PQTS+ teams across complex organizations?

I usually start by building a unified project charter that outlines goals, responsibilities, and decision gates. At GSK, I introduced weekly touchpoints where Quality, Supply, and Procurement could share real-time updates using a live dashboard. We tracked metrics like packaging readiness, supplier validation, and tech transfer progress. I also encourage early engagement—get QA in the room during sourcing decisions and let R&D see supply chain constraints early. When everyone speaks the same language and operates off the same data, alignment becomes a habit, not an effort.

Can you describe when your coordination helped launch a product ahead of schedule?

Absolutely. Our team at GSK prepared to launch a vaccine across four markets, but we faced tight regulatory clearance and delays in supplier onboarding. I coordinated between Quality and Technical to expedite packaging line validation while sourcing and onboarding a secondary CDMO. Through daily war-room calls and a rapid-response escalation process, we shaved three months off the timeline. The product launched on schedule, and we avoided a projected $8M revenue delay. It was a textbook case of PQTS+ collaboration powering strategic agility.

How do you manage the inevitable tension between speed, cost, and compliance?

That’s the golden triangle, right? In my experience, transparency and scenario planning are key. For example, I’ll present teams with tiered options—say, a low-cost supplier with a longer qualification timeline versus a premium vendor ready to go. This approach lets stakeholders make informed trade-offs early. I also make compliance non-negotiable. We can’t cut corners, especially in healthcare. But we can design more innovative pathways—like concurrent validations or risk-based documentation reviews—to move fast without compromising Quality. Balance comes from proactive planning and clear decision criteria.

What role do data and digital tools play in coordinating PQTS+ efforts?

A huge role. I’ve led ERP and Power BI integrations that transformed how teams communicate. Instead of emailing spreadsheets, we shared dashboards showing live updates on inventory, supplier qualification status, or artwork approval. That visibility reduced miscommunication and delays. At Advanced Oncotherapy, our ERP upgrade cut stock discrepancies by 40% and made our PQTS+ meetings far more strategic. When everyone sees the same truth in real-time, you unlock speed, trust, and better decisions.

How do you support R&D integration from a supply chain perspective?

Early engagement is essential. I always try to embed supply chain representation in R&D planning sessions. This method helps flag potential sourcing or packaging challenges before the formulation is finalized. At GSK, I partnered with R&D to fast-track CDMO onboarding for clinical trials, which shaved months off development timelines. Supply chain isn’t just about logistics—it’s about being a strategic enabler of innovation. By understanding R&D’s goals and constraints, we can co-create more robust, scalable, and launch-ready solutions.

How do you uphold quality standards during rapid launches?

You build quality into the process from day one. That means partnering closely with QA to establish critical checkpoints—supplier audits, CAPA tracking, and packaging validations. I also emphasize documentation discipline and leverage digital tools to manage compliance workflows. We embedded a zero-defect goal for our top suppliers during a recent launch, backed by real-time deviation monitoring. The result? Fewer surprises during regulatory audits and smoother launches. Quality isn’t a hurdle—it’s the foundation of sustainable speed.

What metrics or KPIs do you use to measure successful PQTS+ collaboration?

I look at both operational and strategic KPIs. Operationally, things like On-Time In-Full (OTIF), deviation closure rate, and supplier conformance. Strategically, I monitor time-to-launch, cost avoidance, and audit readiness scores. But I also pay attention to engagement—how often are teams updating shared dashboards? Are issues escalated proactively? At GSK, we improved supplier delivery scores by 20% through better PQTS+ coordination, which we tracked in a shared performance cockpit. Metrics matter, but the behaviors behind them are what drives success.

What’s one challenge you’ve faced when launching a global product—and how did you overcome it?

One of the biggest was coordinating artwork and labeling across three countries, each with different regulatory requirements and language needs. Delays in approvals risked missing the product launch window. I set up a cross-regional task force with weekly sprints, aligned the suppliers with Quality on mockup timelines, and used a shared platform to track every step. We also built in buffer time for last-minute changes. The launch happened on time, and we avoided a multimillion-dollar delay. It reinforced how vital tight coordination is in global rollouts.

How do you see PQTS+ collaboration evolving in the healthcare space?
I see it becoming more digital, data-driven, and predictive. With AI and advanced analytics, we’ll move from reactive coordination to proactive orchestration. Imagine systems that flag supplier risks before impacting timelines or forecasting capacity constraints based on R&D inputs. Also, with the growing emphasis on global health equity, we’ll need more agile, inclusive PQTS+ models to launch products across diverse markets. But one thing won’t change—collaboration. Technology can support it, but people make it work. I will always focus on building trust and shared purpose across every launch.